Eli Lilly's stock has surged nearly 400% in five years, but with shares now above $1,150, investors face a key question: does the long-term case still hold, or is it time to rethink the classic buy-and-hold approach
Most of Jim Cramer's commentary on "Mad Money" is known for its quick-fire buy or sell calls, but sometimes he steps back to share a broader investment philosophy. When asked about Eli Lilly (LLY) during a recent Lightning Round, Cramer didn't offer a simple trade recommendation. Instead, he described the pharmaceutical giant as a stock to be owned for the long haul, not actively traded-a stance that reflects his confidence in the company's underlying business strength and earnings durability.
That perspective is rooted in Eli Lilly's remarkable performance. As of late July 2026, LLY shares were trading near $1,155, down from a record high of $1,249 earlier in the month. The stock has climbed 7.8% year to date and delivered a staggering 53% gain over the past 12 months. Over the last five years, Eli Lilly's total return has reached 397%, far outpacing the S&P 500's 69% gain for the same period. Such numbers have reinforced the view that Lilly's business model can withstand short-term volatility and reward patient investors.
Growth Drivers and Market Position
The company's recent success is largely tied to its GLP-1 drug franchise, which includes Mounjaro and Zepbound-two products that have driven exceptional revenue growth. International expansion, such as Mounjaro's addition to China's National Reimbursement Drug List, has further boosted demand. The recent FDA approval of Foundayo, a once-daily oral GLP-1 therapy, could expand the addressable market by appealing to patients who prefer pills over injections. If Foundayo gains traction, it may extend Lilly's growth runway even further.
Financial results underscore this momentum. In the first quarter of 2026, Eli Lilly reported revenue of $19.8 billion, up 56% from the prior year, and non-GAAP earnings per share of $8.55, a 156% increase. The company raised its full-year revenue guidance to a range of $82 billion to $85 billion, with projected non-GAAP EPS between $35.50 and $37.00. These figures highlight the scale of Lilly's recent growth and the market's high expectations for continued performance.
Upcoming Earnings and Investor Focus
Looking ahead to the company's second-quarter earnings report on August 5, analysts polled by Zacks expect Eli Lilly to post EPS of $6.71 on revenue of $20.26 billion. While the projected 30% revenue growth marks a slowdown from the previous quarter's 56% surge, it reflects tougher year-over-year comparisons rather than a fundamental shift in demand. Investors will be watching closely for updates on Foundayo's adoption, supply and pricing for Zepbound, and any changes to full-year guidance. Another upward revision could reinforce the argument for holding the stock through market cycles.
Beyond the numbers, Eli Lilly has made strategic moves to support long-term growth. The company recently announced a $750 million investment with Resilience to expand U.S. manufacturing capacity, a move expected to create 400 new jobs and signal management's confidence in sustained demand. In the first quarter alone, Lilly announced four acquisitions-Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics-demonstrating a commitment to pipeline diversification. The company also joined Illumina's Billion Cell Atlas project, leveraging artificial intelligence for drug discovery across vast genetic datasets.
Long-Term Perspective and Market Risks
For investors, the question is whether Eli Lilly's business fundamentals justify its current valuation, especially after such a dramatic run-up. The company's ability to consistently raise guidance and deliver on ambitious growth targets has supported the "own, don't trade" thesis so far. Yet, as with any high-flying stock, there are risks: competition in the GLP-1 space is intensifying, regulatory scrutiny could increase, and future growth may not match the pace of recent years. Investors should weigh these factors alongside the company's track record and strategic investments.
While some market watchers debate whether to lock in gains or stay the course, the decision ultimately depends on individual risk tolerance, time horizon, and portfolio goals. As seen with other high-profile companies, such as those discussed in recent coverage of shifting bets in the semiconductor sector, even dominant players can face periods of volatility and changing investor sentiment.
At its current price, Eli Lilly remains a case study in the rewards-and challenges-of long-term investing in a rapidly evolving sector. The next earnings report and management's guidance will be key signals for those weighing whether to hold, add, or trim their positions.
Understanding the difference between trading and owning a stock is crucial for investors navigating volatile markets. Trading typically involves short-term bets on price movements, which can be influenced by news, sentiment, or technical factors. Owning, by contrast, is about believing in a company's ability to compound value over years through innovation, market leadership, and operational execution. For stocks like Eli Lilly, where the business case is built on durable competitive advantages and a robust pipeline, the decision to hold through ups and downs may align with a long-term wealth-building strategy-but only if the underlying fundamentals remain intact.
